Nov05

FROM THE PIPELINE | Yaso Therapeutics Yaso-GEL promises to prevent pregnancy and STIs and fill an unmet need in the market

Monday, 05 November 2018 Written by // Mary Weitzel, Barbara North Series // From the Pipeline Tags // contraceptive, STIs, women

We at Yaso Therapeutics are developing a vaginal gel, called Yaso-GEL, that uses a single proprietary drug to prevent pregnancy as well as genital herpes, gonorrhea, and chlamydia. The gel is mucoadhesive, non-irritating, relatively low-cost, and stable. Yaso-GEL aims to be an MPT that can fill the need for non-hormonal contraceptives and protect women from sexually transmitted infections (STIs).

Oct17

FROM THE PIPELINE | Monoclonal antibodies as future MPT products

Wednesday, 17 October 2018 Written by // Kevin Whaley Series // From the Pipeline Tags // contraceptive, HIV, manufacturing, monoclonal antibodies

Monoclonal antibodies are engineered proteins derived from a single parent cell and have been used in a diverse range of therapeutic applications due to their versatility and specificity. At Mapp Biopharmaceutical, Inc., we believe monoclonal antibodies are promising candidates for multipurpose prevention technologies (MPTs) when formulated as topical (e.g., films and rings) or injectable products. Systemic antibodies may have multiple effector functions – like complement binding (CDC) and binding to monocytes (ADCC) – while mucosal mechanisms agglutination and trapping in mucus are less widely discussed, but are crucial for the protection of mucosal surfaces. Systemically and mucosally delivered antibodies have demonstrated efficacy in SHIV prevention studies. In this post, we describe some of the important progress to date on monoclonal antibodies as future MPTs.

Oct16

Young people are leading the charge of the HIV prevention movement

Tuesday, 16 October 2018 Written by // Erin McKelle Tags // HIV, prevention, young people, youth

HIV prevention has come to the forefront of youth activism and public health advocacy, as young people aged 15-24 account for 35% of new HIV infections worldwide. In fact, as we work to curb the HIV epidemic, they are the only age group to experience a recent increase in HIV infections. Young people are disproportionately impacted by HIV and face unique challenges in protecting their sexual health as they navigate complex biological and social transitions into adulthood. In that spirit, the FDA recently approved PrEP (Pre-Exposure Prophylaxis) for adolescents, which has huge implications for empowering young people to prevent HIV exposure or transmission.

<<  2 3 4 5 6 [78 9 10 11  >>  

Recent Posts

Any thoughts? Contact us to learn more about the submission process.
The IMPT is the first & only initiative dedicated to advancing the field of multipurpose prevention technologies (MPTs), products that combine HIV prevention, other STI prevention, and contraception.

IMPT Secretariat
1750 Howe Avenue, Suite 550
Sacramento, CA 95825
IMPT@cami-health.org

The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, a social impact organization dedicated to improving the health of women and their families worldwide. CAMI Health is housed at the Public Health Institute (PHI).

This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.
© Copyright 2020, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.